Ülke: Birleşik Krallık
Dil: İngilizce
Kaynak: MHRA (Medicines & Healthcare Products Regulatory Agency)
Dihydrocodeine tartrate
M & A Pharmachem Ltd
N02AA08
Dihydrocodeine tartrate
30mg
Oral tablet
Oral
Schedule 5 (CD Inv)
Valid as a prescribable product
BNF: 04070200; GTIN: 5056205100200 5056205100217
5HDGDOORIWKLVOHDIOHWFDUHIXOO\EHIRUH\RXVWDUWWDNLQJ
WKLVPHGLFLQHEHFDXVHLWFRQWDLQVLPSRUWDQWLQIRUPDWLRQ
IRU\RX
.HHSWKLVOHDIOHW
Belgenin tamamını okuyun
OBJECT 1 DIHYDROCODEINE 30MG TABLETS Summary of Product Characteristics Updated 20-Jun-2019 | M & A Pharmachem Ltd • 1. Name of the medicinal product • 2. Qualitative and quantitative composition • 3. Pharmaceutical form • 4. Clinical particulars • 4.1 Therapeutic indications • 4.2 Posology and method of administration • 4.3 Contraindications • 4.4 Special warnings and precautions for use • 4.5 Interaction with other medicinal products and other forms of interaction • 4.6 Fertility, pregnancy and lactation • 4.7 Effects on ability to drive and use machines • 4.8 Undesirable effects • 4.9 Overdose • 5. Pharmacological properties • 5.1 Pharmacodynamic properties • 5.2 Pharmacokinetic properties • 5.3 Preclinical safety data • 6. Pharmaceutical particulars • 6.1 List of excipients • 6.2 Incompatibilities • 6.3 Shelf life • 6.4 Special precautions for storage • 6.5 Nature and contents of container • 6.6 Special precautions for disposal and other handling • 7. Marketing authorisation holder • 8. Marketing authorisation number(s) • 9. Date of first authorisation/renewal of the authorisation • 10. Date of revision of the text 1. Name of the medicinal product Dihydrocodeine Tablets BP 30 mg 2. Qualitative and quantitative composition Each tablet contains 30 mg Dihydrocodeine Tartrate 3. Pharmaceutical form Tablet 4. Clinical particulars 4.1 Therapeutic indications Dihydrocodeine tablets are indicated for the relief of moderate to severe pain. 4.2 Posology and method of administration For oral administration The analgesic effect is not materially enhanced by increasing the dose above that recommended below; in severe cases the interval between doses should be reduced to obtain the requisite analgesic cover. Dihydrocodeine tablets are best taken with or after food. Adults and children over 12 years: 1 tablet every four to six hours or at the discretion of the practitioner. Maximum dose in 24 hours 180mg (6 tablets). Elderly A reduced adult dose is recommended, at the Belgenin tamamını okuyun